Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations

The success of antibodies targeting Programmed cell death protein 1 (PD-1) and its ligand L1 (PD-L1) in cancer treatment and the need for improving response rates has led to an increased demand for the development of combination therapies with anti-PD-1/PD-L1 blockers as a backbone. As more and more...

Descripción completa

Detalles Bibliográficos
Autores principales: Lemaire, Vincent, Shemesh, Colby S., Rotte, Anand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485537/
https://www.ncbi.nlm.nih.gov/pubmed/34598713
http://dx.doi.org/10.1186/s13046-021-02111-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485537/
https://www.ncbi.nlm.nih.gov/pubmed/34598713
http://dx.doi.org/10.1186/s13046-021-02111-5

Ejemplares similares